28 March 2026 in Yakut Medical Journal
This article presents a retrospective analysis of percutaneous liver tumor core biopsies for histological diagnosis confirmation from 2021 to 2024, according to data from the Yakutsk Republican Oncology Dispensary. During the study period, a significant increase in the rate of morphological verification of liver tumors, including hepatocellular carcinoma (HCC), was recorded. In modern international practice, HCC diagnosis is based on the results of noninvasive diagnostic methods (CT/MRI with contrast, serum biomarkers), and core biopsy is used selectively. However, in the Russian Federation, morphological verification of the diagnosis is an absolutely mandatory requirement for the prescription of systemic drug therapy for HCC (targeted, immuno-oncology), in accordance with the clinical guidelines of the Russian Ministry of Health, except in cases where the diagnosis is reliably established based on clinical and instrumental criteria (CT/MRI with contrast) in patients with confirmed liver cirrhosis. This underscores the uniquely important role of liver trephine biopsy in the diagnosis of HCC in the Russian Federation.